What is the current valuation of the India deep vein-thrombosis-treatment market?

The market valuation was $49.14 Million in 2024. Read More

What is the projected market size for the India deep vein-thrombosis-treatment market by 2035?

The market is expected to reach $109.46 Million by 2035. Read More

What is the expected CAGR for the India deep vein-thrombosis-treatment market during the forecast period 2025 - 2035?

The expected CAGR is 7.55% during the forecast period. Read More

Which drug class segment had the highest valuation in 2024?

The Anticoagulants segment had a valuation ranging from $20.0 Million to $45.0 Million. Read More

What is the valuation range for the Heparin segment in 2024?

The Heparin segment had a valuation range from $15.0 Million to $30.0 Million. Read More

Which mode of administration is projected to have significant growth in the market?

The Injectable mode of administration had a valuation range from $20.0 Million to $45.0 Million. Read More

What distribution channel is expected to dominate the market in 2025?

Retail Pharmacies are projected to have a valuation range from $20.0 Million to $45.0 Million. Read More

What is the expected valuation for the Drugs treatment segment by 2035?

The Drugs treatment segment is expected to reach a valuation range from $25.0 Million to $55.0 Million. Read More

How does the homecare segment compare to hospitals in terms of market valuation?

The Homecare segment had a valuation range from $10.0 Million to $25.0 Million, which is lower than the Hospitals segment, valued from $20.0 Million to $45.0 Million. Read More

India Deep Vein Thrombosis Treatment Market

Q: What are the key players in the India deep vein-thrombosis-treatment market?

Key players include Bayer AG, Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi S.A., Pfizer Inc., AstraZeneca PLC, Roche Holding AG, and Novartis AG. Read More

ID: MRFR/HC/50514-HCR 200 Pages Vikita Thakur Last Updated: September 17, 2026

India Deep Vein Thrombosis Treatment Market Research Report By Drug Class (Anticoagulants, Heparin, Others), By Treatment (Surgery, Drugs, Others), By Mode Of Administration (Injectable, Oral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By End-User (Hospitals, Homecare, Specialty Clinics, Others) -Forecast to 2035

India Deep Vein Thrombosis Treatment Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.55%

2024 Market Size$ 49.14 Million

2025 Market Size$ 52.85 Million

2035 Market Size$ 109.46 Million

Key Players

Bayer AG

Bristol-Myers Squibb Company

Johnson & Johnson

Sanofi S.A.

Pfizer Inc.

AstraZeneca PLC

Trends

Rising Awareness and Education
Technological Advancements in Treatment
Shift Towards Personalized Medicine

Opportunities

Rising Healthcare Expenditure
Increasing Incidence of Risk Factors
Growing Focus on Preventive Healthcare

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Drug Class (USD Million)
  1. 4.1.1 Anticoagulants
  2. 4.1.2 Heparin
  3. 4.1.3 Others
2. 4.2 Life Sciences, BY Treatment (USD Million)
  1. 4.2.1 Surgery
  2. 4.2.2 Drugs
  3. 4.2.3 Others
3. 4.3 Life Sciences, BY Mode Of Administration (USD Million)
  1. 4.3.1 Injectable
  2. 4.3.2 Oral
  3. 4.3.3 Others
4. 4.4 Life Sciences, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacies
5. 4.5 Life Sciences, BY End-User (USD Million)
  1. 4.5.1 Hospitals
  2. 4.5.2 Homecare
  3. 4.5.3 Specialty Clinics
  4. 4.5.4 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bayer AG (DE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi S.A. (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Pfizer Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca PLC (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche Holding AG (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis AG (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY DRUG CLASS
3. 6.3 INDIA MARKET ANALYSIS BY TREATMENT
4. 6.4 INDIA MARKET ANALYSIS BY MODE OF ADMINISTRATION
5. 6.5 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 INDIA MARKET ANALYSIS BY END-USER
7. 6.7 KEY BUYING CRITERIA OF LIFE SCIENCES
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF LIFE SCIENCES
10. 6.10 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
12. 6.12 SUPPLY / VALUE CHAIN: LIFE SCIENCES
13. 6.13 LIFE SCIENCES, BY DRUG CLASS, 2024 (% SHARE)
14. 6.14 LIFE SCIENCES, BY DRUG CLASS, 2024 TO 2035 (USD Million)
15. 6.15 LIFE SCIENCES, BY TREATMENT, 2024 (% SHARE)
16. 6.16 LIFE SCIENCES, BY TREATMENT, 2024 TO 2035 (USD Million)
17. 6.17 LIFE SCIENCES, BY MODE OF ADMINISTRATION, 2024 (% SHARE)
18. 6.18 LIFE SCIENCES, BY MODE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
19. 6.19 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
20. 6.20 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
21. 6.21 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
22. 6.22 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY MODE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
  5. 7.2.5 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Get Free Sample PDF

Certified Researchers

Customize Report

India Deep Vein Thrombosis Treatment Market Segmentation

India Deep Vein Thrombosis Treatment Market By Drug Class (USD Million, 2025-2035)

Anticoagulants
Heparin
Others

India Deep Vein Thrombosis Treatment Market By Treatment (USD Million, 2025-2035)

Surgery
Drugs
Others

India Deep Vein Thrombosis Treatment Market By Mode Of Administration (USD Million, 2025-2035)

Injectable
Oral
Others

India Deep Vein Thrombosis Treatment Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

India Deep Vein Thrombosis Treatment Market By End-User (USD Million, 2025-2035)

Hospitals
Homecare
Specialty Clinics
Others

Get Free Sample PDF

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035